JMP Securities Downgrades Achillion Pharmaceuticals (ACHN) to Market Perform

Cowen 'Mixed' on Achillion (ACHN) JNJ Deal But Says Shares Undervalued

Cowen analyst Phil Nadeau reiterated an Outperform rating on Achillion Pharmaceuticals (NASDAQ: ACHN) following the HCV deal with JNJ. The analyst notes the deal diversifies risk but perhaps also lowers reward.

Nadeau commented, "We have a mixed opinion of the deal and view it as having some positive and some negative ramifications for ACHN shareholders. On the positive side, in addition to potentially meaningfully accelerating the development of a triple combination regimen containing an ACHN-discovered molecule, the collaboration... More

JNJ Deal De-Risks Achillion's (ACHN) HCV Program, Leerink Partners; PT Cut to $16

Leerink Partners analyst Howard Liang is out positive on Achillion Pharmaceuticals (NASDAQ: ACHN) following the HCV deal with JNJ, saying it de-risks the program and increasing the shots on goal. However, the firm lowered their price target to $16.00 (from $25.00) while maintaining an Outperform rating.

Liang commented, "We... More

William Blair Upgrades Achillion (ACHN) to Outperform; Janssen Deal Makes 'Tremendous Sense', D Program Has Potential, Says Analyst

(Updated - May 20, 2015 9:07 AM EDT)

William Blair upgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Market Perform to Outperform and raised its price target to $18 (from $14).

Yesterday Janssen announced that it has entered into an exclusive worldwide license and collaboration arrangement with Achillion to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH 3102, ACH-3422 and sovaprevir.

In the view of analyst Y. Katherine Xu, ACH 3102 drove the deal. Despite dashed M&A hopes and weakness in the... More

Baird 'Lukewarm' on Achillion's (ACHN) Janssen/J&J Hep C Deal; PT Cut to $10

Baird analyst Brian Skorney cut his price target on Achillion Pharmaceuticals (NASDAQ: ACHN) to $10.00 (from $16.00) and maintained a Neutral rating saying they are "lukewarm" on the Janssen/J&J Hep C deal.

Skorney commented, "Instead of the $20 takeout bulls were looking for,... More

UBS Downgrades Achillion Pharmaceuticals (ACHN) to Neutral

UBS downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to Neutral.

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $10.68 yesterday.

Janssen (JNJ), Achillion (ACHN) Enter Exclusive, Global HCV Collaboration

Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into an exclusive worldwide license and collaboration arrangement with Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422 and sovaprevir.

A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that is planned to be explored will feature... More